Antimicrobial Susceptibility Testing in Secondary Viral Co-infections: Principles, Methods, and Clinical Integration

Secondary bacterial co-infections arising from primary viral disease represent a critical driver of morbidity, mortality, and antimicrobial use in veterinary populations. The immunological disruption caused by viral pathogens (including epithelial barrier compromise, mucociliary dysfunction, and leukocyte dysregulation) creates a permissive niche for opportunistic bacteria. Antimicrobial susceptibility testing (AST) in this context provides the empirical foundation for selecting targeted therapy, curbing the emergence of resistance, and distinguishing bacterial superinfection from viral cytopathology. This reference article details the biological basis, methodological approaches, interpretive frameworks, and clinical limitations of AST in the setting of secondary viral co-infections across veterinary species.

1. Pathophysiological Basis of Secondary Bacterial Invasion after Viral Infection

Respiratory and enteric viruses in domestic animals predispose the host to bacterial colonization through several well-characterized mechanisms. Physical disruption of epithelial tight junctions and ciliary function is observed after infection with influenza A virus in swine, canine distemper virus in dogs, and infectious bronchitis virus in poultry. Concurrent immune modulation (including suppression of alveolar macrophage phagocytosis, reduced neutrophil chemotaxis, and altered cytokine profiles) further impairs bacterial clearance [1].

In a study of H3N2 canine influenza virus co-infection with Enterococcus faecalis in dogs, investigators demonstrated that viral replication in bronchial epithelial cells preceded bacterial adherence and translocation across the basement membrane [2]. Similar synergism has been documented in poultry where Newcastle disease virus or infectious bronchitis virus infection increases the susceptibility of the respiratory tract to Escherichia coli (avian pathogenic E. coli, APEC) and Ornithobacterium rhinotracheale. In swine, porcine reproductive and respiratory syndrome virus infection of alveolar macrophages impairs bactericidal activity and facilitates secondary infection with Streptococcus suis or Haemophilus parasuis.

2. Samples and Timing for AST in Viral Co-infections

Appropriate sample selection is essential for meaningful AST results in the context of ongoing viral infection. Samples should be collected from the site of suspected bacterial involvement (lower respiratory tract via transtracheal wash or bronchoalveolar lavage, nasal swabs in upper respiratory disease, or fecal samples in enteric co-infections). The timing of collection is critical: samples obtained too early (within 48 hours of viral symptom onset) may reflect normal flora rather than true secondary pathogens. Conversely, samples collected after prolonged hospitalization or empirical antimicrobial therapy risk yielding resistant hospital-acquired strains [3, 4].

For poultry, pooled tracheal swabs or lung tissue homogenates from acutely affected birds are preferred. In large animal practice, bronchoalveolar lavage fluid from cattle with bovine respiratory syncytial virus or bovine herpesvirus 1 infection should be cultured quantitatively to differentiate clinically relevant bacterial loads from contaminating upper airway flora.

3. Core AST Methodologies

AST methodologies applicable to secondary bacterial isolates from viral co-infections follow standard clinical microbiology protocols. The choice of method depends on laboratory resources, bacterial growth characteristics, and the need for quantitative minimum inhibitory concentration (MIC) data.

Table 1 summarizes the principal AST methods and their applications in the veterinary co-infection context.

Disk diffusion remains the most accessible method for routine veterinary diagnostics. Standardized protocols from the Clinical and Laboratory Standards Institute (CLSI) provide species-specific (e.g., canine, feline, bovine, poultry) and anatomical site-specific breakpoints. Broth microdilution is the reference standard for MIC determination and is indispensable for detecting subtle shifts in susceptibility that precede clinical resistance.

4. Interpretation of AST Results in Co-infected Patients

Interpretation of AST results from secondary bacterial isolates requires integration of several factors beyond the raw SIR or MIC value. The following considerations are particularly relevant in the context of viral co-infection.

First, polymicrobial infections are common. A respiratory sample from a dog with canine influenza may yield both E. faecalis and E. coli [2]. Testing each isolate individually does not capture potential synergistic or antagonistic interactions. Combination AST (checkerboard broth microdilution or time-kill assays) can identify rational combination therapy in refractory cases, though these methods are rarely available outside research laboratories.

Second, the distinction between colonization and infection is a clinical judgment that AST cannot resolve. A positive culture with a fully susceptible organism does not confirm that the organism is the cause of clinical deterioration. Quantitative culture (( \geq 10^3 ) CFU/mL for BAL fluid in dogs and cats) and cytological evidence of intracellular bacteria or degenerative neutrophils provide supporting evidence.

Third, antimicrobial resistance genes may be horizontally transferred among bacterial species in the co-infected niche. Plasmid-mediated resistance (e.g., extended-spectrum beta-lactamases in E. coli or mecA-mediated methicillin resistance in Staphylococcus pseudintermedius) can emerge rapidly under selective pressure from antimicrobial therapy.

Fourth, the host's antimicrobial pharmacokinetics may be altered by viral infection. Fever, dehydration, and altered protein binding (due to acute phase protein changes) can affect drug distribution. MIC data must be interpreted alongside expected tissue penetration (e.g., macrolides and tetracyclines concentrate well in respiratory epithelium; aminoglycosides are less effective in purulent exudates).

5. Clinical Decision Workflow

A structured workflow integrates sample collection, rapid viral diagnostics, bacterial culture, and AST to guide therapeutic decisions. The Mermaid diagram below illustrates this process.

flowchart TD
    A[Clinical case: Suspected viral infection with signs of bacterial co-infection], > B[Collect appropriate sample (BAL, tracheal wash, nasal swab, tissue)]
    B, > C[Perform rapid viral diagnostic (PCR, antigen ELISA, virus isolation)]
    C, > D[Viral pathogen identified?]
    D, Yes, > E[Viral infection confirmed; assess for bacterial co-infection]
    D, No, > F[Consider alternative primary etiology; proceed with bacterial culture]
    E, > G[Gram stain and cytology: identify morphology and inflammation]
    G, > H[Bacterial culture on selective and non-selective media]
    H, > I[Isolate identification: MALDI-TOF MS or biochemical panel]
    I, > J[Perform AST: disk diffusion or broth microdilution]
    J, > K[Interpret results using species-specific CLSI breakpoints]
    K, > L[Select antimicrobial based on spectrum, tissue penetration, and safety]
    L, > M[Monitor clinical response; re-culture if deterioration occurs]
    M, > N[Document resistance findings for local antibiogram]

The workflow emphasizes that AST should never be performed on samples from a patient with pure viral infection and no cytological evidence of bacterial involvement. Indiscriminate culture and AST from viral cases contribute to the overinterpretation of commensal flora and drive unnecessary antimicrobial use.

6. AST in Specific Veterinary Viral Co-infection Scenarios

6.1 Canine Influenza Virus and Enterococcus faecalis

Co-infection of dogs with H3N2 canine influenza virus and E. faecalis has been documented in China [2]. E. faecalis isolates in this context often show intrinsic resistance to cephalosporins, clindamycin, and aminoglycosides (low-level). Vancomycin susceptibility is typically preserved, though vancomycin-resistant enterococci (VRE) have been reported in companion animals with prior antimicrobial exposure. AST for enterococci requires testing of ampicillin (MIC breakpoint (\leq 4 , \mu g/mL) for susceptible), vancomycin, and linezolid. High-level gentamicin synergy testing ((500 , \mu g/mL) disk) is indicated if a bactericidal combination is needed.

6.2 Avian Influenza and Pasteurella multocida in Poultry

In poultry flocks experiencing low-pathogenicity avian influenza (LPAI) or highly pathogenic avian influenza (HPAI) H5N1, secondary infection with P. multocida (the agent of fowl cholera) is a recognized sequel. AST of P. multocida from affected birds typically shows susceptibility to penicillin, oxytetracycline, and sulfonamide-trimethoprim combinations. Resistance to tetracyclines has been reported in flocks with historical medicated feed use. Disk diffusion using Mueller-Hinton agar supplemented with 5% sheep blood is the standard method.

6.3 Bovine Respiratory Syncytial Virus and Mannheimia haemolytica

The bovine respiratory disease complex (BRDC) frequently involves primary viral infection (bovine respiratory syncytial virus, bovine herpesvirus 1, parainfluenza 3 virus) followed by secondary bacterial pneumonia with M. haemolytica or P. multocida. AST for M. haemolytica must include tulathromycin, florfenicol, danofloxacin, and gamithromycin. MIC creep against macrolides has been observed in some North American feedlot populations. Broth microdilution in cation-adjusted Mueller-Hinton broth with 5% lysed horse blood is the recommended method.

6.4 Feline Upper Respiratory Viruses and Bordetella bronchiseptica

Feline herpesvirus 1 and feline calicivirus predispose cats to secondary infection with Bordetella bronchiseptica. This fastidious gram-negative coccobacillus grows slowly on selective media. AST by disk diffusion requires Bordetella agar or charcoal agar; standard breakpoints are not fully established for all drugs. Doxycycline is the empirical drug of choice, but susceptibility to amoxicillin-clavulanate, enrofloxacin, and pradofloxacin should be confirmed given geographic variation in resistance [5].

7. Antimicrobial Resistance Trends in Secondary Co-infections

The literature consistently reports that bacterial isolates from viral co-infection cases carry higher rates of antimicrobial resistance compared to isolates from bacterial pneumonia alone. This phenomenon is multifactorial: viral infection often leads to empirical antimicrobial therapy before culture results are available; hospitalized patients may acquire nosocomial resistant strains; and the inflamed, necrotic tissue environment may select for subpopulations with reduced susceptibility [6, 4].

In a study of secondary bacterial infections in hospitalized patients with COVID-19 (used here as a comparative model for veterinary intensive care), Acinetobacter baumannii and Klebsiella pneumoniae isolates showed high rates of carbapenem resistance [3, 7]. While these specific pathogens are less common in veterinary medicine, analogous trends have been observed in veterinary intensive care units with Pseudomonas aeruginosa and Staphylococcus pseudintermedius.

Chagas et al. isolated Bacillus spp. from pediatric patients with respiratory viral co-infection and reported variable susceptibility to vancomycin, linezolid, and daptomycin [5]. The relevance of Bacillus spp. in veterinary co-infections is species dependent; Bacillus cereus can act as an opportunistic pathogen in dogs and cats with compromised mucosal barriers.

8. Molecular AST and Emerging Technologies

Traditional phenotypic AST requires 18 to 48 hours of culture, a delay that can be clinically significant in rapidly deteriorating patients with viral co-infections. Molecular methods for resistance gene detection offer faster turnaround times but cannot detect resistance mediated by porin loss, efflux pump upregulation, or novel mutations not represented on the detection panel.

Real-time PCR assays for common resistance genes (mecA in staphylococci, blaCTX-M in Enterobacterales, tet(M) in enterococci, and erm(B) in gram-positive cocci) can be performed directly on clinical samples, bypassing the need for pure culture. Whole genome sequencing (WGS) of bacterial isolates provides comprehensive resistance gene profiling and phylogenetic context for outbreak investigations. In a veterinary diagnostics setting, WGS can link a resistant isolate from a co-infected case to a hospital environmental reservoir or to previously colonized in-contact animals.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) can identify bacterial species from colonies in minutes, enabling earlier selection of appropriate AST panels. Some MALDI-TOF MS algorithms can also detect beta-lactamase activity by monitoring degradation products of cephalosporin substrates.

9. Limitations and Pitfalls in AST for Co-infections

Several important limitations apply when performing AST in the context of secondary viral co-infections.

First, sample contamination with normal flora is common, especially in nasal swabs and oropharyngeal samples from dogs and cats. The presence of E. faecalis or coagulase-negative staphylococci may reflect overgrowth rather than true infection.

Second, fastidious or slow-growing bacteria (e.g., Mycoplasma spp., Bordetella spp., Histophilus somni) require specialized media and incubation conditions. Standard disk diffusion protocols may not be validated for these organisms, and broth microdilution panels may not include relevant antimicrobials.

Third, biofilms formed by bacteria on damaged respiratory epithelium can shield organisms from antimicrobial action even when AST indicates in vitro susceptibility. The presence of alginate-producing Pseudomonas aeruginosa or polysaccharide intercellular adhesin (PIA) producing staphylococci should prompt consideration of biofilm-active agents (e.g., rifampin combinations or high-dose fluoroquinolones).

Fourth, immunosuppression induced by the viral infection (e.g., leukopenia in canine parvovirus infection, lymphopenia in feline leukemia virus infection) alters the host's ability to clear bacteria even when appropriate antimicrobials are selected. AST predicts drug activity against the pathogen but does not account for host immune status.

10. Conclusion

Antimicrobial susceptibility testing is an indispensable component of managing secondary bacterial co-infections that complicate primary viral disease in veterinary patients. The methodological rigor of AST (whether by disk diffusion, broth microdilution, or molecular detection of resistance determinants) must be matched by thoughtful clinical interpretation that accounts for sample quality, polymicrobial flora, host immune status, and pharmacokinetic alterations induced by viral infection. The growing body of evidence documenting elevated resistance rates among isolates from co-infected cases underscores the urgency of integrating AST into routine viral disease management protocols. As molecular diagnostics and computational tools become more accessible, the integration of rapid viral detection with real-time phenotypic and genotypic AST will improve antimicrobial stewardship and clinical outcomes across companion animal, livestock, and avian populations.

References

[1] Boianelli A, Sharma-Chawla N, Bruder D, et al. Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection. Front Cell Infect Microbiol. 2016. URL: https://pubmed.ncbi.nlm.nih.gov/27379214/

[2] Zhou L, Sun H, Song S, et al. H3N2 canine influenza virus and Enterococcus faecalis coinfection in dogs in China. BMC Vet Res. 2019. URL: https://pubmed.ncbi.nlm.nih.gov/30975135/

[3] Mollasharifi T, Zamani M, Gharib A. Evaluation of Secondary Bacterial Infections and Determination of Antibiogram Susceptibility Testing in Hospitalized Patients with COVID-19. Iran J Pathol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/40034925/

[4] Khurana S, Singh P, Sharad N, et al. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33966856/

[5] Chagas ALD, Araújo JCDS, Vieira JDG, et al. Isolation, identification, and sensitivity profile of Bacillus spp. in co-infection with respiratory viruses. Front Pediatr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41674788/

[6] Abdel-Hamid RM, Bayoumi A, Abdellateif MS, et al. Bacterial co-infections in cancer patients with COVID-19: predictors and antimicrobial resistance trends. J Infect Dev Ctries. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39288390/

[7] Sleiman A, Abdelkhalek P, Doumat G, et al. The under investigated facet of the COVID-19 pandemic: Molecular analysis of secondary bacterial infections at a COVID dedicated intensive care unit within a tertiary care center in Lebanon. Front Med (Lausanne). 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36817795/